Neha420

Antiviral Drugs Market Size, Share, Regional Sales, Growth, Industry Trends | Forecast 2026

Jul 30th, 2021
120
Never
Not a member of Pastebin yet? Sign Up, it unlocks many cool features!
  1. The Global Antiviral Drugs Market is set to gain impetus from the improvements in research collaborations of industry giants to develop state-of-the-art therapeutics. Besides, the increasing prevalence of viral diseases would impact the market positively. Fortune Business Insights™ published this information in a recent study, titled, “Antiviral Drugs Market Size, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2019-2026.” The study further mentions that the antiviral drugs market size is projected to reach USD 44.2 billion by 2026, thereby exhibiting a CAGR of 3.2% during the forecast period. However, it stood at USD 36.1 billion in 2018.
  2.  
  3. For more information in the analysis of this report, visit:https://www.fortunebusinessinsights.com/antiviral-drugs-market-102190
  4.  
  5. Highlights of the Report
  6.  
  7. Extensive analysis of the antiviral drugs market trends, growth drivers, hindrances, opportunities, and challenges.
  8. Profiles of the key organizations and their business strategies.
  9. Quantitative analysis from 2019 to 2026 to help the stakeholders in capitalizing on the existing opportunities.
  10. Detailed information about every possible segment present in the market.
  11. Fortune Business Insights™ profiles some of the most prominent companies operating in the antiviral drugs market. They are as follows:
  12.  
  13. Abbvie, Inc.
  14. Novartis AG
  15. Gilead Sciences
  16. Mylan N.V.
  17. GlaxoSmithKline
  18. Merck & Co., Inc.
  19. Janssen Pharmaceuticals, Inc.
  20. Bristol-Myers Squibb Company
  21. Other key market players
  22. High Demand for Targeted & Specific Treatment Regimen to Boost Growth
  23.  
  24. One of the most common forms of viral infection that is occurring across the world is HIV. The diagnosis rate of HIV is improving gradually owing to the refinement of surveillance by using biological and demographic data. The World Health Organization (WHO) stated that in the year 2018, approximately 37.9 million people were affected by HIV. However, around 770,000 people died of this disease. It proves that the rising cases of HIV is fueling the demand for specific and targeted treatment regimen. Apart from that, the rising prevalence of influenza and its efficient diagnosis are set to drive the antiviral drugs market growth in the coming years.
  25.  
  26. Request a Sample Copy of the Global Antiviral Drugs Market Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antiviral-drugs-market-102190
  27.  
  28. Study by FSU Aid in Battling HIV & Hepatitis B; Gilead Submits sNDA Application to FDA
  29.  
  30. Key enterprises present in the market are constantly striving to bring about new treatment options for the patients suffering from viral infections. They are aiming to gain the maximum antiviral drugs market share by bagging FDA approvals to broaden product portfolio. Educational institutions are also actively participating in conducting studies to discover new drugs. Below are two of the latest industry developments:
  31.  
  32. January 2020: The researchers of Florida State University (FSU) are set to open new doors for innovative treatment options for more than 36 million HIV-infected people across the globe. The new treatment options would also help treating the chronically ill patients with hepatitis B. For the first time, their work has established the mechanism accountable for how two antiviral drugs inhibit viruses.
  33. April 2019: Gilead Sciences, Inc., a biotechnology company that researches, develops, and commercializes drugs, based in California, announced its submission of a supplemental New Drug Application (sNDA) to the FDA. It was done for its emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets called Descovy for pre-exposure prophylaxis (PrEP) to prevent sexually transmitted HIV-1 infection in those who are at risk.
  34. TOC of Antiviral Drugs Market:
  35.  
  36. Introduction
  37. Research Scope
  38. Market Segmentation
  39. Research Methodology
  40. Definitions and Assumptions
  41. Executive Summary
  42. Market Dynamics
  43. Market Drivers
  44. Market Restraints
  45. Market Opportunities
  46. Key Insights
  47. Key Industry Trends
  48. Recent industry developments such as mergers & acquisitions
  49. regulatory and reimbursement scenario for key countries
  50. Prevalence of Key viral diseases, in major countries, 2018
  51. New Product Launches
  52. Global Antiviral Drugs Market Analysis, Insights and Forecast, 2015-2026
  53. Key Findings / Summary
  54. Market Analysis, Insights and Forecast – By Disease Indication
  55. Hepatitis
  56. Human Immunodeficiency Virus (HIV)
  57. Influenza
  58. Others
  59. Market Analysis, Insights and Forecast – By Drug Class
  60. Integrase Inhibitors
  61. Polymerase Inhibitors
  62. Protease Inhibitors
  63. Combination Drugs
  64. Reverse Transcriptase Inhibitors
  65. Others
  66. Market Analysis, Insights and Forecast – By Distribution Channel
  67. Hospital Pharmacy
  68. Retail Pharmacy
  69. Online Channel
  70. Market Analysis, Insights and Forecast – By Region
  71. North America
  72. Europe
  73. Asia Pacific
  74. Latin America
  75. Middle East & Africa
  76. North America Antiviral Drugs Market Analysis, Insights and Forecast, 2015-2026
  77. Key Findings / Summary
  78. Market Analysis – By Disease Indication
  79. Hepatitis
  80. Human Immunodeficiency Virus (HIV)
  81. Influenza
  82. Others
  83. Market Analysis – By Drug Class
  84. Integrase Inhibitors
  85. Polymerase Inhibitors
  86. Protease Inhibitors
  87. Combination Drugs
  88. Reverse Transcriptase Inhibitors
  89. Others
  90. Market Analysis – By Distribution Channel
  91. Hospital Pharmacy
  92. Retail Pharmacy
  93. Online Channel
  94. Market Analysis – By Country
  95. U.S.
  96. Canada
  97. Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2015-2026
  98. Key Findings / Summary
  99. Market Analysis – By Disease Indication
  100. Hepatitis
  101. Human Immunodeficiency Virus (HIV)
  102. Influenza
  103. Others
  104. Market Analysis – By Drug Class
  105. Integrase Inhibitors
  106. Polymerase Inhibitors
  107. Protease Inhibitors
  108. Combination Drugs
  109. Reverse Transcriptase Inhibitors
  110. Others
  111. Market Analysis – By Distribution Channel
  112. Hospital Pharmacy
  113. Retail Pharmacy
  114. Online Channel
  115. Market Analysis – By Country/Sub-region
  116. U.K.
  117. Germany
  118. France
  119. Spain
  120. Italy
  121. Scandinavia
  122. Rest of Europe
  123. Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/antiviral-drugs-market-102190
  124.  
  125. About Us:
  126.  
  127. Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
  128.  
  129. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
  130.  
  131. At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
  132.  
  133. Contact Us:
  134.  
  135. Fortune Business Insights™ Pvt. Ltd.
  136.  
  137. 308, Supreme Headquarters,
  138.  
  139. Survey No. 36, Baner,
  140.  
  141. Pune-Bangalore Highway,
  142.  
  143. Pune - 411045, Maharashtra, India.
  144.  
  145. Phone:
  146.  
  147. US: +1 424 253 0390
  148.  
  149. UK: +44 2071 939123
  150.  
  151. APAC: +91 744 740 1245
  152.  
  153. Email: sales@fortunebusinessinsights.com
RAW Paste Data